Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ather Siddiqi

Pulmonary Disease The Woodlands, TX Medical Doctor

NPI 1700874716 CMS profile 350107

1111 Medical Plaza Dr, Suite 250, The Woodlands, TX 77380

Open in the dashboard

General payments

$12,510

548 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,344,723 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Ather Siddiqi of The Woodlands, TX is reported in the CMS Open Payments database as having received $12,510 across 548 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $1,344,723 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 83rd percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,845 84
2024 General $1,858 85
2023 General $2,579 125
2022 General $2,231 99
2021 General $570 14
2020 General $2,110 62
2019 General $1,317 79

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ather Siddiqi
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Ather Siddiqi were reported at $1,845. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Ather Siddiqi Pulmonary Disease median Middle half National median
2019 $1,317 $377 $109–$1,340 $163
2020 $2,110 $230 $56–$907 $114
2021 $570 $269 $68–$1,072 $132
2022 $2,231 $390 $100–$1,457 $149
2023 $2,579 $419 $114–$1,659 $160
2024 $1,858 $476 $123–$1,818 $164
2025 $1,845 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Inspire Medical Systems, Inc. $1,610 13 payments
  2. Electromed, Inc. $1,040 73 payments
  3. Insmed, Inc. $967 22 payments
  4. AbbVie, Inc. $914 40 payments
  5. AstraZeneca Pharmaceuticals LP $903 45 payments
  6. Actelion Pharmaceuticals US, Inc. $787 35 payments
  7. GlaxoSmithKline, LLC. $700 47 payments
  8. Regeneron Healthcare Solutions, Inc. $697 30 payments
  9. Genzyme Corporation $567 31 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $416 22 payments
  11. Other $3,909 190 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,035 529 payments
  2. Travel and Lodging $981 1 payment
  3. Education $493 18 payments
Products named General payments · program years 2019–2025
  1. Inspire Upper Airway Stimulation System $1,318 3 payments
  2. SMARTVEST $985 66 payments
  3. Arikayce $967 22 payments
  4. TEFLARO $830 36 payments
  5. UPTRAVI $787 35 payments
  6. OPSUMIT $674 31 payments
  7. DUPIXENT Immunology $575 29 payments
  8. YUPELRI $504 21 payments
  9. Vabomere $369 4 payments
  10. DUPIXENT Immunology And Inflammation $366 13 payments
  11. Other $7,018 378 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 35 drugs

Part D claims

1,889

Median for Pulmonary Disease: 936

Drug cost

$790,271

Median for Pulmonary Disease: $487,987

Branded share of claims

66%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 283 $259,016
Opsumit Macitentan Brand 11 $135,900
Bosentan Generic 11 $109,395
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 94 $69,896
Breo Ellipta Fluticasone/Vilanterol Brand 91 $45,932
Spiriva Respimat Tiotropium Bromide Brand 43 $28,984
Orenitram Er Treprostinil Diolamine Brand 22 $26,965
Symbicort Budesonide/Formoterol Fumarate Brand 43 $15,091
Atrovent Hfa Ipratropium Bromide Brand 20 $11,095
Advair Hfa Fluticasone Propion/Salmeterol Brand 23 $9,897

The 10 drugs with the highest cost, of 35 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 52 billing codes

Paid by Medicare

$531,383

Of which drugs: $327,822

Medicare patients

659

Average age 76

Services billed

14,290

338 women, 321 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Ischemic heart disease 48%
COPD 43%
Atrial fibrillation 36%
Diabetes 34%
Heart failure 34%
Chronic kidney disease 31%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, omalizumab, 5 mg J2357 Office 11 7,515 $225,078

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $233
  • Regeneron Healthcare Solutions, Inc. $98
$330 — —
ARALAST
  • Takeda Pharmaceuticals U.S.A., Inc. $138
$138 — —
FASENRA
  • AstraZeneca Pharmaceuticals LP $124
$124 — —
YUPELRI
  • Mylan Specialty L.P. $115
$115 — —
TEZSPIRE
  • AstraZeneca Pharmaceuticals LP $94
  • Amgen Inc. $18
$112 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

548 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record